Skip to main content
Erschienen in: Applied Health Economics and Health Policy 5/2011

01.09.2011 | Original Research Article

Excess costs associated with patients with pulmonary arterial hypertension in a US privately insured population

verfasst von: Noam Y. Kirson, PhD, Howard G. Birnbaum, Jasmina I. Ivanova, Tracy Waldman, Vijay Joish, Todd Williamson

Erschienen in: Applied Health Economics and Health Policy | Ausgabe 5/2011

Einloggen, um Zugang zu erhalten

Abstract

Background

Pulmonary arterial hypertension (PAH) is a rare but fatal disease. Little is known about the economic burden associated with PAH patients in the US.

Objectives

The objective of this study was to estimate excess direct costs associated with privately insured PAH patients in the US.

Methods

From a privately insured claims database (>8 million beneficiaries, 2002–7), 471 patients with PAH were identified using the criteria: two or more claims for primary pulmonary hypertension (PH), International Classification of Diseases, ninth edition, clinical modification (ICD-9-CM) code 416.0; no left heart disease, lung diseases, chronic thromboembolic PH or miscellaneous PH diagnoses within 12 months prior or 1 month after the initial PH claim (index date); one or more claim for right heart catheterization (RHC) within 6 months prior to any PH claim or one or more claim for echocardiogram within 6 months prior to a specialist-diagnosed PH claim; aged 18–64 years. Patients with PAH were matched demographically to controls without PH. Patients were followed as long as continuously eligible; mean follow-up of PAH patients was 24.8 months. Chi-squared tests were used to compare baseline co-morbidities. Wilcoxon rank-sum tests were used to compare direct (medical and pharmaceutical) patient-month costs to insurers.

Results

The average age for PAH patients was 52.2 years, and 55.8% were women. Compared with controls, PAH patients had significantly higher baseline rates of co-morbidities (e.g. essential hypertension, diabetes mellitus and congestive heart failure) and a higher mean Charlson Co-morbidity Index score. Mean direct patient-month costs (year 2007 values) were $US2023 for PAH patients and $US498 for controls (p< 0.0001), yielding excess costs of $US1525. Sensitivity analysis restricting the sample to patients diagnosed following RHC yielded a 64% increase in excess costs relative to the original sample. Regarding cost drivers, inpatient services accounted for 45%, outpatient and other services for 38% and prescription drugs for 15% of total direct healthcare costs per patient-month in PAH patients. Circulatory/respiratory system-related patient-month costs were $US724 among PAH patients and $US114 among controls (p< 0.0001).

Conclusions

Patients with PAH had substantially higher costs and co-morbidity than controls, with circulatory/respiratory system-related costs accounting for 40% of excess costs. The high burden of illness suggests opportunities for savings from improved management.
Literatur
1.
Zurück zum Zitat McLaughlin VV, Archer SL, Badesch DB, et al. AC-CF/AHA 2009 expert consensus document on pulmonary arterial hypertension. J Am Coll Cardiol 2009; 53(17): 1573–619PubMedCrossRef McLaughlin VV, Archer SL, Badesch DB, et al. AC-CF/AHA 2009 expert consensus document on pulmonary arterial hypertension. J Am Coll Cardiol 2009; 53(17): 1573–619PubMedCrossRef
2.
Zurück zum Zitat Thenappan T, Shah SJ, Rich S, et al. A USA-based registry for pulmonary arterial hypertension: 1982–2006. Eur Respir J 2007; 30: 1103–10PubMedCrossRef Thenappan T, Shah SJ, Rich S, et al. A USA-based registry for pulmonary arterial hypertension: 1982–2006. Eur Respir J 2007; 30: 1103–10PubMedCrossRef
4.
Zurück zum Zitat Galie N, Manes A, Branzi A. Emerging medical therapies for pulmonary arterial hypertension. Prog Cardiovasc Dis 2002; 45(3): 213–24PubMedCrossRef Galie N, Manes A, Branzi A. Emerging medical therapies for pulmonary arterial hypertension. Prog Cardiovasc Dis 2002; 45(3): 213–24PubMedCrossRef
5.
Zurück zum Zitat Benedict N, Seybert A, Mathier M. Evidence-based pharmacologic management of pulmonary arterial hypertension. Clin Ther 2007; 29(10): 2134–53PubMedCrossRef Benedict N, Seybert A, Mathier M. Evidence-based pharmacologic management of pulmonary arterial hypertension. Clin Ther 2007; 29(10): 2134–53PubMedCrossRef
7.
Zurück zum Zitat Simonneau G, Galie N, Rubin LJ, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004; 43: 5–12SCrossRef Simonneau G, Galie N, Rubin LJ, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004; 43: 5–12SCrossRef
8.
Zurück zum Zitat Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009 Jun 30; 54(1 Suppl.): S43–54PubMedCrossRef Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009 Jun 30; 54(1 Suppl.): S43–54PubMedCrossRef
10.
Zurück zum Zitat Michelakis ED, Tymchak W, Noga M, et al. Long-term treatment with oral sildenafil is safe and improved functional capacity and hemodynamics in patients with pulmonary arterial hypertension. Circulation 2003; 108(17): 2066–9PubMedCrossRef Michelakis ED, Tymchak W, Noga M, et al. Long-term treatment with oral sildenafil is safe and improved functional capacity and hemodynamics in patients with pulmonary arterial hypertension. Circulation 2003; 108(17): 2066–9PubMedCrossRef
11.
Zurück zum Zitat Hoeper MM, Faulenbach C, Golpon H, et al. Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension. Eur Respir J 2004; 24(6): 1007–10PubMedCrossRef Hoeper MM, Faulenbach C, Golpon H, et al. Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension. Eur Respir J 2004; 24(6): 1007–10PubMedCrossRef
12.
Zurück zum Zitat Angalakuditi M, Edgell E, Beardsworth A, et al. Treatment patterns and resource utilization and costs among patients with pulmonary arterial hypertension in the United States. J Med Econ 2010; 13(3): 393–402PubMedCrossRef Angalakuditi M, Edgell E, Beardsworth A, et al. Treatment patterns and resource utilization and costs among patients with pulmonary arterial hypertension in the United States. J Med Econ 2010; 13(3): 393–402PubMedCrossRef
13.
Zurück zum Zitat Peacock AJ, Murphy NF, McMurray JJV, et al. An epidemiological study of pulmonary arterial hypertension. Eur Respir J 2007; 30: 104–9PubMedCrossRef Peacock AJ, Murphy NF, McMurray JJV, et al. An epidemiological study of pulmonary arterial hypertension. Eur Respir J 2007; 30: 104–9PubMedCrossRef
14.
15.
Zurück zum Zitat Champion HC, Michelakis ED, Hassoun PM. Comprehensive invasive and noninvasive approach to the right ventricle pulmonary circulation unit: state of the art and clinical and research implications. Circulation 2009; 120: 992–1007PubMedCrossRef Champion HC, Michelakis ED, Hassoun PM. Comprehensive invasive and noninvasive approach to the right ventricle pulmonary circulation unit: state of the art and clinical and research implications. Circulation 2009; 120: 992–1007PubMedCrossRef
16.
Zurück zum Zitat Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40(5): 373–83PubMedCrossRef Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40(5): 373–83PubMedCrossRef
17.
Zurück zum Zitat Romano PS, Roos LL, Jollis J. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data. J Clin Epidemiol 1993; 46(10): 1075–9PubMedCrossRef Romano PS, Roos LL, Jollis J. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data. J Clin Epidemiol 1993; 46(10): 1075–9PubMedCrossRef
18.
19.
Zurück zum Zitat Einarson TR, Granton JT, Vicente C, et al. Cost-effectiveness of treprostinil versus epoprostenol in patients with pulmonary arterial hypertension: a Canadian analysis. Can Respir J 2005 Nov-Dec; 12(8): 419–25PubMed Einarson TR, Granton JT, Vicente C, et al. Cost-effectiveness of treprostinil versus epoprostenol in patients with pulmonary arterial hypertension: a Canadian analysis. Can Respir J 2005 Nov-Dec; 12(8): 419–25PubMed
20.
Zurück zum Zitat Wilkens H, Grimminger F, Hoeper M, et al. Burden of pulmonary arterial hypertension in Germany. Respir Med 2010 Jun; 104(6): 902–10PubMedCrossRef Wilkens H, Grimminger F, Hoeper M, et al. Burden of pulmonary arterial hypertension in Germany. Respir Med 2010 Jun; 104(6): 902–10PubMedCrossRef
21.
Zurück zum Zitat Macchia A, Marchioli R, Marfisi R, et al. A meta-analysis of trials of pulmonary hypertension: a clinical condition looking for drugs and research methodology. Am Heart J 2007; 153: 1037–47PubMedCrossRef Macchia A, Marchioli R, Marfisi R, et al. A meta-analysis of trials of pulmonary hypertension: a clinical condition looking for drugs and research methodology. Am Heart J 2007; 153: 1037–47PubMedCrossRef
22.
Zurück zum Zitat Ghofrani HA, Wilkins MW, Rich S. Uncertainties in the diagnosis and treatment of pulmonary arterial hypertension. Circulation 2008; 118: 1195–201PubMedCrossRef Ghofrani HA, Wilkins MW, Rich S. Uncertainties in the diagnosis and treatment of pulmonary arterial hypertension. Circulation 2008; 118: 1195–201PubMedCrossRef
23.
Zurück zum Zitat Galiè N, Palazzini M, Manes A. Pulmonary arterial hypertension: from the kingdom of the near-dead to multiple clinical trial meta-analyses. Eur Heart J 2010 Sep; 31(17): 2080–6PubMedCrossRef Galiè N, Palazzini M, Manes A. Pulmonary arterial hypertension: from the kingdom of the near-dead to multiple clinical trial meta-analyses. Eur Heart J 2010 Sep; 31(17): 2080–6PubMedCrossRef
24.
Zurück zum Zitat Chen YF, Jowett S, Barton P, et al. Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation. Health Technol Assess 2009 Oct; 13(49): 1–320PubMed Chen YF, Jowett S, Barton P, et al. Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation. Health Technol Assess 2009 Oct; 13(49): 1–320PubMed
Metadaten
Titel
Excess costs associated with patients with pulmonary arterial hypertension in a US privately insured population
verfasst von
Noam Y. Kirson, PhD
Howard G. Birnbaum
Jasmina I. Ivanova
Tracy Waldman
Vijay Joish
Todd Williamson
Publikationsdatum
01.09.2011
Verlag
Springer International Publishing
Erschienen in
Applied Health Economics and Health Policy / Ausgabe 5/2011
Print ISSN: 1175-5652
Elektronische ISSN: 1179-1896
DOI
https://doi.org/10.2165/11592430-000000000-00000

Weitere Artikel der Ausgabe 5/2011

Applied Health Economics and Health Policy 5/2011 Zur Ausgabe